KR102709778B1 - 미세부수체 불안정성(msi) 암의 예방 및 치료를 위한 공유된 종양 신생항원을 기반으로 한 범용 백신 - Google Patents

미세부수체 불안정성(msi) 암의 예방 및 치료를 위한 공유된 종양 신생항원을 기반으로 한 범용 백신 Download PDF

Info

Publication number
KR102709778B1
KR102709778B1 KR1020207000642A KR20207000642A KR102709778B1 KR 102709778 B1 KR102709778 B1 KR 102709778B1 KR 1020207000642 A KR1020207000642 A KR 1020207000642A KR 20207000642 A KR20207000642 A KR 20207000642A KR 102709778 B1 KR102709778 B1 KR 102709778B1
Authority
KR
South Korea
Prior art keywords
ser
leu
arg
pro
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207000642A
Other languages
English (en)
Korean (ko)
Other versions
KR20200029443A (ko
Inventor
알프레도 니코시아
엘리사 스카르셀리
귀도 레오니
아르민 람
Original Assignee
노우스콤 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노우스콤 아게 filed Critical 노우스콤 아게
Publication of KR20200029443A publication Critical patent/KR20200029443A/ko
Application granted granted Critical
Publication of KR102709778B1 publication Critical patent/KR102709778B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207000642A 2017-07-12 2018-07-12 미세부수체 불안정성(msi) 암의 예방 및 치료를 위한 공유된 종양 신생항원을 기반으로 한 범용 백신 Active KR102709778B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17181026 2017-07-12
EP17181026.0 2017-07-12
PCT/EP2018/069032 WO2019012082A1 (en) 2017-07-12 2018-07-12 UNIVERSAL VACCINE BASED ON SHARED TUMOR NEO-ANTIGENS FOR THE PREVENTION AND TREATMENT OF MICRO-SATELLITE INSTABILITY CANCER (MSI)

Publications (2)

Publication Number Publication Date
KR20200029443A KR20200029443A (ko) 2020-03-18
KR102709778B1 true KR102709778B1 (ko) 2024-09-26

Family

ID=59366234

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207000642A Active KR102709778B1 (ko) 2017-07-12 2018-07-12 미세부수체 불안정성(msi) 암의 예방 및 치료를 위한 공유된 종양 신생항원을 기반으로 한 범용 백신

Country Status (19)

Country Link
US (1) US11578109B2 (enExample)
EP (1) EP3652606B1 (enExample)
JP (1) JP7274223B2 (enExample)
KR (1) KR102709778B1 (enExample)
CN (1) CN111328420B (enExample)
AU (1) AU2018298849B2 (enExample)
BR (1) BR112020000590A2 (enExample)
CA (1) CA3069047A1 (enExample)
DK (1) DK3652606T5 (enExample)
ES (1) ES2940087T3 (enExample)
FI (1) FI3652606T3 (enExample)
HU (1) HUE061840T2 (enExample)
IL (1) IL271966B2 (enExample)
MX (1) MX2020000413A (enExample)
NZ (1) NZ759940A (enExample)
PL (1) PL3652606T3 (enExample)
PT (1) PT3652606T (enExample)
SG (1) SG11202000250PA (enExample)
WO (1) WO2019012082A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3827265A1 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Cancer vaccines for kidney cancer
IL321691A (en) 2018-07-26 2025-08-01 Curevac Netherlands B V arid1a, cdkn2a, kmt2b, kmt2d, tp53 and pten vaccines against cancer
IL280113B2 (en) 2018-07-26 2025-11-01 Curevac Netherlands B V Cancer vaccines for uterine cancer
IL280112B2 (en) 2018-07-26 2025-11-01 Curevac Netherlands B V Cancer vaccines for breast cancer
CA3106562A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Off-the-shelf cancer vaccines
CA3106573A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for colorectal cancer
TWI852977B (zh) * 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
WO2020163802A1 (en) * 2019-02-07 2020-08-13 Arizona Board Of Regents On Behalf Of Arizona State University Cancer specific frameshift vaccines
CN114980920A (zh) 2019-11-18 2022-08-30 詹森生物科技公司 基于突变体calr和jak2的疫苗及其用途
WO2021228999A1 (en) * 2020-05-12 2021-11-18 Institut Curie Neoantigenic epitopes associated with sf3b1 mutations
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
US20240218019A1 (en) * 2021-04-06 2024-07-04 Board Of Regents, The University Of Texas System Methods and compositions comprising mhc class i peptides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187508A2 (en) 2015-05-20 2016-11-24 The Broad Institute Inc. Shared neoantigens

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922315A (en) 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
US8053552B2 (en) * 2002-04-18 2011-11-08 Mtm Laboratories, Ag Neopeptides and methods useful for detection and treatment of cancer
WO2004092338A2 (en) * 2003-04-11 2004-10-28 Diadexus, Inc. Compositions, splice variants and methods relating to cancer specific genes and proteins
CN1824325A (zh) * 2005-12-16 2006-08-30 武汉大学 人乳头病毒dna嵌合疫苗及制备方法和应用
BRPI0717651A2 (pt) * 2006-10-17 2013-12-24 Oncotherapy Science Inc Vacinas de peptídeo para cânceres que expressam polipeptídeos mphosph1 ou depdc1
TW201102081A (en) * 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
US8685896B2 (en) 2009-05-29 2014-04-01 Morphosys Ag Collection and methods for its use
SG183945A1 (en) * 2010-04-09 2012-10-30 Oncotherapy Science Inc Cdca5 peptides and vaccines including the same
ES2575980T3 (es) * 2011-03-24 2016-07-04 Institut National De La Santé Et De La Recherche Médicale (Inserm) Mutante de HSP110 dominante negativo y su uso en el pronóstico y el tratamiento de cánceres
DK2742133T3 (en) * 2011-08-12 2017-12-04 Oncotherapy Science Inc MPHOSPH1 PEPTIDES AND VACCINES CONTAINING THESE
JP5890769B2 (ja) * 2012-12-13 2016-03-22 ループレヒト−カルルス・ウニヴェルジテート・ハイデルベルクＲｕｐｒｅｃｈｔ−Ｋａｒｌｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｈｅｉｄｅｌｂｅｒｇ がんの予防及び治療のためのｍｓｉ特異的なフレームシフトペプチド（ｆｓｐ）
US9205140B2 (en) * 2012-12-13 2015-12-08 Ruprecht-Karls-Universität MSI-specific frameshift peptides (FSP) for prevention and treatment of cancer
KR101810840B1 (ko) * 2012-12-13 2017-12-20 루프레히트-칼스-유니페어지테트 하이델베르크 암의 예방 및 치료용 msi-특이적 프레임쉬프트 펩티드(fsp)
US20140235456A1 (en) * 2012-12-17 2014-08-21 Virginia Tech Intellectual Properties, Inc. Methods and Compositions for Identifying Global Microsatellite Instability and for Characterizing Informative Microsatellite Loci
US11098367B2 (en) * 2014-01-27 2021-08-24 Yale University Methods of identifying patients responsive to immunotherapeutic strategies
CN106350578A (zh) * 2015-07-13 2017-01-25 中国人民解放军第二军医大学 Ny-eso-1在微卫星不稳定性肠癌的诊断和治疗中的应用
US12150980B2 (en) 2015-07-30 2024-11-26 Modernatx, Inc. Concatemeric peptide epitope RNAs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187508A2 (en) 2015-05-20 2016-11-24 The Broad Institute Inc. Shared neoantigens

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
S M Woerner 외, Systematic identification of genes with coding microsatellites mutated in DNA mismatch repair-deficient cancer cells, Inter J Cancer, 2001.07.01., Vol.93, No.1.
Shen Luhui 외, Abstract 469: Progress towards developing a universal, prophylactic cancer vaccine, Cancer Res, 2013.04.15., Vol.73.
Yvette Schwitalle 외, Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells, Cacner Immun., 2004.11.25., Vol.4.

Also Published As

Publication number Publication date
EP3652606B1 (en) 2023-01-11
RU2019144505A3 (enExample) 2021-08-12
WO2019012082A9 (en) 2019-05-02
PT3652606T (pt) 2023-03-16
AU2018298849A1 (en) 2020-01-02
JP7274223B2 (ja) 2023-05-16
PL3652606T3 (pl) 2023-04-24
AU2018298849B2 (en) 2022-07-14
SG11202000250PA (en) 2020-02-27
DK3652606T3 (da) 2023-03-13
NZ759940A (en) 2023-07-28
CN111328420A (zh) 2020-06-23
IL271966A (en) 2020-02-27
RU2019144505A (ru) 2021-08-12
IL271966B2 (en) 2025-01-01
BR112020000590A2 (pt) 2020-07-14
US11578109B2 (en) 2023-02-14
US20200222519A1 (en) 2020-07-16
FI3652606T3 (fi) 2023-03-16
IL271966B1 (en) 2024-09-01
MX2020000413A (es) 2020-09-28
DK3652606T5 (da) 2024-08-26
EP3652606A1 (en) 2020-05-20
KR20200029443A (ko) 2020-03-18
CN111328420B (zh) 2023-07-25
CA3069047A1 (en) 2019-01-17
HUE061840T2 (hu) 2023-08-28
JP2020532288A (ja) 2020-11-12
WO2019012082A1 (en) 2019-01-17
ES2940087T3 (es) 2023-05-03

Similar Documents

Publication Publication Date Title
KR102709778B1 (ko) 미세부수체 불안정성(msi) 암의 예방 및 치료를 위한 공유된 종양 신생항원을 기반으로 한 범용 백신
AU2023251441A1 (en) RNA containing composition for treatment of tumor diseases
AU2017235661B2 (en) Oligonucleotide probes and uses thereof
AU2017234120B2 (en) Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
AU2023214237A1 (en) Modified polynucleotides for the production of biologics and proteins associated with human disease
TW202321448A (zh) 利用重組環狀rna改善蛋白質轉譯的組合物及方法
AU2016381496B2 (en) Plant traits conferred by isolated polynucleotides and polypeptides
KR102719587B1 (ko) 아데노-관련 바이러스 생산을 위한 포유동물 세포
KR102630357B1 (ko) 단백질 발현이 어려운 다중-부위 ssi 세포
AU2021203894A1 (en) Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
AU2019316556B2 (en) Methods for assessing the risk of developing progressive multifocal leukoencephalopathy caused by john cunningham virus by genetic testing
JP2003088388A (ja) 新規な全長ｃＤＮＡ
KR20150129847A (ko) 융합 단백질 및 이들의 방법
JP2003135075A (ja) 新規な全長ｃＤＮＡ
EP1165784A2 (en) Nucleic acids including open reading frames encoding polypeptides; "orfx"
AU2017289886A1 (en) Engineered parasites for delivering protein to the central nervous system (CNS)
KR20220054401A (ko) 감염의 숙주 rna 바이오마커의 신속한 조기-검출 및 인간의 covid-19 코로나바이러스 감염의 조기 식별을 위한 시스템, 방법 및 조성물
JP2003304888A (ja) 化合物の毒性予測のための方法
AU2017336160B2 (en) Screening methods using olfactory receptors and novel compounds identified using the same
AU2016295122A1 (en) Genetic testing for predicting resistance of pseudomonas species against antimicrobial agents
KR20110110030A (ko) 뇌종양의 재발 가능성 및 생존 예후 예측용 조성물 및 이를 포함하는 키트
JP2003235573A (ja) 糖尿病性腎症マーカーおよびその利用
KR101978399B1 (ko) 자궁내막증에 대한 진단 마커로서의 돌연변이 유전자 및 이의 용도
KR20110069283A (ko) Ｔｈｅｒｍｏｃｏｃｃｕｓ ｓｐ. ＮＡ1 으로부터의 유용한 유전자들
RU2792843C2 (ru) Универсальная вакцина на основе общих опухолевых неоантигенов для предупреждения и лечения форм рака с микросателлитной нестабильностью (msi)

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PA0102 Application to register extension of term of patent right following delayed registration

Protection beyond ip right term event data comment text: Claim Total Quantity : 0, Period Limitation Text : 160

St.27 status event code: A-4-4-G10-G15-tad-PA0102

PR1102 Extension of patent period due to registration delay

Protection beyond ip right term event data comment text: Claim Total Quantity : 0, Period Limitation Text : 160

St.27 status event code: A-4-4-G10-G17-tad-PR1102